Arai Takayuki, Okato Atsushi, Kojima Satoko, Idichi Tetsuya, Koshizuka Keiichi, Kurozumi Akira, Kato Mayuko, Yamazaki Kazuto, Ishida Yasuo, Naya Yukio, Ichikawa Tomohiko, Seki Naohiko
Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
Cancer Sci. 2017 Oct;108(10):2088-2101. doi: 10.1111/cas.13331. Epub 2017 Aug 19.
Analysis of our original microRNA (miRNA) expression signature of patients with advanced renal cell carcinoma (RCC) showed that microRNA-10a-5p (miR-10a-5p) was significantly downregulated in RCC specimens. The aims of the present study were to investigate the antitumor roles of miR-10a-5p and the novel cancer networks regulated by this miRNA in RCC cells. Downregulation of miR-10a-5p was confirmed in RCC tissues and RCC tissues from patients treated with tyrosine kinase inhibitors (TKI). Ectopic expression of miR-10a-5p in RCC cell lines (786-O and A498 cells) inhibited cancer cell migration and invasion. Spindle and kinetochore-associated protein 1 (SKA1) was identified as an antitumor miR-10a-5p target by genome-based approaches, and direct regulation was validated by luciferase reporter assays. Knockdown of SKA1 inhibited cancer cell migration and invasion in RCC cells. Overexpression of SKA1 was observed in RCC tissues and TKI-treated RCC tissues. Moreover, analysis of The Cancer Genome Atlas database demonstrated that low expression of miR-10a-5p and high expression of SKA1 were significantly associated with overall survival in patients with RCC. These findings showed that downregulation of miR-10a-5p and overexpression of the SKA1 axis were highly involved in RCC pathogenesis and resistance to TKI treatment in RCC.
对我们最初的晚期肾细胞癌(RCC)患者微小RNA(miRNA)表达特征的分析表明,微小RNA-10a-5p(miR-10a-5p)在RCC标本中显著下调。本研究的目的是探讨miR-10a-5p的抗肿瘤作用以及该miRNA在RCC细胞中调控的新型癌症网络。在RCC组织和接受酪氨酸激酶抑制剂(TKI)治疗的患者的RCC组织中证实了miR-10a-5p的下调。在RCC细胞系(786-O和A498细胞)中异位表达miR-10a-5p可抑制癌细胞迁移和侵袭。通过基于基因组的方法鉴定出纺锤体和动粒相关蛋白1(SKA1)是miR-10a-5p的抗肿瘤靶点,并通过荧光素酶报告基因检测验证了直接调控。敲低SKA1可抑制RCC细胞中的癌细胞迁移和侵袭。在RCC组织和TKI治疗的RCC组织中观察到SKA1的过表达。此外,对癌症基因组图谱数据库的分析表明,miR-10a-5p的低表达和SKA1的高表达与RCC患者的总生存期显著相关。这些发现表明,miR-10a-5p的下调和SKA1轴的过表达高度参与了RCC的发病机制以及RCC对TKI治疗的耐药性。